Elabscience

Recombinant Human Fetuin-A/AHSG protein (His tag)

Product Code:
 
PDMH100105
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
 
Generally lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
PDMH100105-20ug20ug£178.00
Quantity:
PDMH100105-100ug100ug£237.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
Fetuin-A;AHSG
Accession:
P02765
Background:
Fetuin-A, also known as Alpha-2-HS-Glycoprotein (AHSG), belongs to the Fetuin family, is a plasma binding protein, and is more abundant in fetal than adult blood. It is involved in several functions, such as endocytosis, brain development and the formation of bone tissue. Fetuins are carrier proteins like albumin. Fetuin-A forms soluble complexes with calcium and phosphate and thus is a carrier of otherwise insoluble calcium phosphate. Thus Fetuin-A is a potent inhibitor of pathological calcification. The circulating levels of fetuin-A, a well-described inhibitor of calcification, regulate the cell-dependent process of osteogenesis. The low circulating fetuin-A levels are associated with a greater prevalence and/or severity of Vascular calcification (VC) and increased risk for all-cause and cardiovascular mortality. However, high circulating fetuin-A levels appear to induce insulin resistance and, in non-dialyzed subjects with diabetic nephropathy, are directly related to VC burden. The emerging role of fetuin-A deficiency as a risk factor in dialysis patients was documented in cross-sectional studies demonstrating a significant correlation with all-cause and cardiovascular mortality. Additionally, Human fetuin-A is a negative acute phase protein involved in inflammatory diseases, thus being a potential physiological regulator of meprin activity. Fetuin-A is a broad-range protease inhibitor. Fetuin-A and cystatin C as endogenous proteolytic regulators of meprin activity broadens our understanding of the proteolytic network in plasma.
Calculated MW:
40.26 kDa
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
58 kDa
Purity:
> 95 % as determined by reducing SDS-PAGE.
Sequence:
Met1-Val367
Target Synonym:
Alpha-2-HS-Glycoprotein;Alpha-2-Z-Globulin;Ba-Alpha-2-Glycoprotein;Fetuin-A;AHSG;FETUA
UNIProt ID:
P02765

Documents